SABS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
25.9M
+10.8%
23.4M
+16.9%
20.0M
+26.8%
15.8M
+24.4%
12.7M
R&D
18.1M
+11.8%
16.2M
+20.7%
13.4M
+24.9%
10.7M
+19.6%
9.0M
SG&A
7.8M
+8.6%
7.2M
+9.2%
6.6M
+30.9%
5.0M
+35.9%
3.7M
Operating Income
-25899000
-10.8%
-23377000
-16.9%
-19997736
-26.8%
-15770231
-24.4%
-12679000
EBITDA
-25098000
-11.2%
-22563965
-17.1%
-19266771
-28.4%
-15006932
-25.7%
-11935000
Net Income
-22300000
+0.8%
-22491000
-19.2%
-18868885
-11.9%
-16860743
-137.1%
45.4M
EPS (Basic)
$-0.24
+14.3%
$-0.28
+20.0%
$-0.35
-483.3%
$-0.06
-112.0%
$0.50
EPS (Diluted)
$-0.24
+14.3%
$-0.28
+20.0%
$-0.35
-1650.0%
$-0.02
+90.5%
$-0.21
Shares (Diluted)
93.2M
+16.9%
79.8M
+48.9%
53.6M
-64.0%
148.9M
+91.2%
77.9M
SAB Biotherapeutics (SABS) — Financials